891 studies found for:    cancer | wake forest
Show Display Options
RSS Create an RSS feed from your search for:
cancer | wake forest
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate Cancer
Conditions: Hot Flashes;   Prostate Cancer
Interventions: Dietary Supplement: soy isoflavones;   Dietary Supplement: soy protein isolate;   Drug: venlafaxine;   Drug: placebo
2 Recruiting A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387;   Drug: Crizotinib
3 Completed
Has Results
National Lung Screening Trial (NLST) Screening
Condition: Lung Cancer
Interventions: Device: low-dose helical computed tomography;   Device: chest radiography
4 Completed Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer
Conditions: Breast Cancer;   Estrogen Receptor-Positive Breast Cancer;   Breast Cancer, Estrogen Receptor-Positive;   ER+ Breast Cancer
Interventions: Drug: entinostat;   Drug: exemestane
5 Completed Genetic Analysis of Hereditary Prostate Cancer
Condition: Prostate Cancer
Intervention:
6 Recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
7 Recruiting A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
Condition: Colon Cancer
Intervention:
8 Recruiting Chemoradiation or Brachytherapy for Rectal Cancer
Condition: Rectal Cancer
Interventions: Radiation: Endo-HDR (if randomized to this arm);   Drug: capecitabine and IMRT (if randomized to this arm);   Radiation: IMRT (intensity modulated radiation therapy);   Drug: FOLFOX6;   Procedure: Surgery
9 Active, not recruiting
Has Results
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Other: hydrocortisone/placebo;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
10 Active, not recruiting Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors
Conditions: Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: questionnaire administration;   Behavioral: exercise intervention;   Procedure: quality-of-life assessment;   Other: survey administration;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
11 Suspended Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
Conditions: Ovarian Mucinous Cystadenocarcinoma;   Ovarian Mucinous Cystadenoma With Proliferating Activity;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Other: quality-of-life assessment;   Drug: carboplatin;   Drug: paclitaxel;   Drug: oxaliplatin;   Drug: capecitabine;   Biological: bevacizumab
12 Active, not recruiting Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Conditions: Childhood Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Clear Cell Sarcoma of the Kidney;   Papillary Renal Cell Carcinoma;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor
Interventions: Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Procedure: conventional surgery;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: carboplatin;   Biological: dactinomycin;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
13 Active, not recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Procedure: therapeutic conventional surgery;   Procedure: computed tomography
14 Active, not recruiting Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Intervention: Other: laboratory biomarker analysis
15 Recruiting Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
16 Active, not recruiting Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
17 Active, not recruiting Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel poliglumex;   Other: clinical observation;   Drug: paclitaxel
18 Completed Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Completed Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer
Conditions: Breast Neoplasms;   Breast Diseases
Intervention: Device: OSNA Breast Cancer System
20 Completed
Has Results
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Biological: pegfilgrastim;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies;   Genetic: genetic linkage analysis;   Drug: docetaxel

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years